PMID- 32234921
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20200420
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 40
IP  - 4
DP  - 2020 Apr
TI  - Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for 
      Pre-treated Metastatic Gastric Cancer.
PG  - 2247-2255
LID - 10.21873/anticanres.14187 [doi]
AB  - BACKGROUND/AIM: The efficacy of treatment using the anti-programmed cell death-1 
      (anti-PD-1) antibody for metastatic gastric cancer (mGC) has been established 
      previously. Exploratory analyses in various types of tumours suggest that prior 
      exposure to immune checkpoint inhibitors can enhance the efficacy of subsequent 
      cytotoxic chemotherapy (CTx). Our aim is to evaluate the efficacy and safety of 
      CTx for mGC after progression on anti-PD-(ligand) 1 [anti-PD-(L)1] antibody. 
      PATIENTS AND METHODS: We retrospectively evaluated patients with mGC who 
      underwent CTx. The patients received CTx after progression on anti-PD-(L)1 
      antibody (cohort A) or as a third-line treatment without prior exposure to 
      anti-PD-(L)1 antibody (cohort B). We evaluated: i) clinical characteristics, ii) 
      efficacies, iii) prognoses, and iv) adverse events (AEs). RESULTS: In cohorts A 
      and B, 16 and 68 patients fulfilled the criteria, respectively. In the univariate 
      analysis, the overall response rate was significantly higher in cohort A compared 
      to cohort B (31% vs. 10%, respectively; Odds Ratio:3.96, 95% Confidence 
      Interval:1.06-14.8, p=0.040). The multivariate analysis showed a similar trend. 
      Immune-related AEs did not worsen and were manageable, while new immune-related 
      AEs were not observed. CONCLUSION: CTx after progression on anti-PD-(L)1 antibody 
      demonstrated a favourable efficacy in intensively treated patients with mGC.
CI  - Copyright(c) 2020, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kato, Kyoko
AU  - Kato K
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
FAU - Narita, Yukiya
AU  - Narita Y
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan 
      yukiya.narita@aichi-cc.jp.
FAU - Mitani, Seiichiro
AU  - Mitani S
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
AD  - Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, 
      Japan.
FAU - Honda, Kazunori
AU  - Honda K
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
FAU - Masuishi, Toshiki
AU  - Masuishi T
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
FAU - Taniguchi, Hiroya
AU  - Taniguchi H
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
AD  - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer 
      Centre Hospital East, Chiba, Japan.
FAU - Kadowaki, Shigenori
AU  - Kadowaki S
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
FAU - Ura, Takashi
AU  - Ura T
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
AD  - Department of Clinical Oncology, National Hospital Organisation Kyoto Medical 
      Centre, Kyoto, Japan.
FAU - Ando, Masashi
AU  - Ando M
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
FAU - Tajika, Masahiro
AU  - Tajika M
AD  - Department of Endoscopy, Aichi Cancer Centre Hospital, Aichi, Japan.
FAU - Muro, Kei
AU  - Muro K
AD  - Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Cytotoxins)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
RN  - KXG2PJ551I (avelumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - B7-H1 Antigen/*antagonists & inhibitors/metabolism
MH  - Cytotoxins/administration & dosage
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Nivolumab/administration & dosage
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/metabolism
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*drug therapy/metabolism/pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anti-PD-(L)1
OT  - chemotherapy
OT  - gastric cancer
OT  - immune checkpoint inhibitor
EDAT- 2020/04/03 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/02/20 00:00 [revised]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
AID - 40/4/2247 [pii]
AID - 10.21873/anticanres.14187 [doi]
PST - ppublish
SO  - Anticancer Res. 2020 Apr;40(4):2247-2255. doi: 10.21873/anticanres.14187.